Log in
Enquire now
‌

US Patent 9732041 Arginine methyltransferase inhibitors and uses thereof

Patent 9732041 was granted and assigned to Epizyme on August, 2017 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors

Contents

Is a
Patent
Patent
0

Patent attributes

Patent Applicant
Epizyme
Epizyme
0
Current Assignee
Epizyme
Epizyme
0
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
0
Patent Number
97320410
Patent Inventor Names
Oscar Miguel Moradei0
Richard Chesworth0
Gideon Shapiro0
Kenneth W. Duncan0
Lei Jin0
Lorna Helen Mitchell0
Paula Ann Boriack-Sjodin0
Date of Patent
August 15, 2017
0
Patent Application Number
150931030
Date Filed
April 7, 2016
0
Patent Citations Received
‌
US Patent 11834455 Carm1 inhibitors and uses thereof
0
Patent Primary Examiner
‌
Kristin Vajda
0
Patent abstract

Described herein are compounds of Formula (I), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds described herein are useful for inhibiting arginine methyltransferase activity. Methods of using the compounds for treating arginine methyltransferase-mediated disorders are also described.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 9732041 Arginine methyltransferase inhibitors and uses thereof

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.